News

BioSpace21h
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B
Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...
Fierce Biotech1d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
STAT22h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Money Morning16h
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
Jim Cramer on Eli Lilly and Company (LLY) – “Buy Hand Over Fist – This GLP-1 Giant Just Crushed Novo”
We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at ...
Novo Nordisk: A Strategy With High Potential For Volatile Times
Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...
pharmaphorum2d
Novo Nordisk builds case for Norditropin successor
In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...